Yumanity Therapeutics (NASDAQ:YMTX) Trading Up 3.4%

Yumanity Therapeutics, Inc. (NASDAQ:YMTXGet Rating)’s stock price was up 3.4% on Friday . The company traded as high as $1.89 and last traded at $1.85. Approximately 146,956 shares changed hands during mid-day trading, a decline of 70% from the average daily volume of 486,027 shares. The stock had previously closed at $1.79.

Yumanity Therapeutics Stock Up 3.4 %

The business has a 50-day simple moving average of $1.67 and a two-hundred day simple moving average of $1.59. The stock has a market capitalization of $20.08 million, a P/E ratio of -0.62 and a beta of 0.35.

Institutional Trading of Yumanity Therapeutics

Large investors have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new position in Yumanity Therapeutics in the first quarter worth $35,000. Citadel Advisors LLC lifted its stake in shares of Yumanity Therapeutics by 54.0% during the third quarter. Citadel Advisors LLC now owns 49,543 shares of the company’s stock valued at $78,000 after acquiring an additional 17,364 shares during the period. Monaco Asset Management SAM acquired a new position in shares of Yumanity Therapeutics during the second quarter valued at $91,000. Renaissance Technologies LLC lifted its stake in shares of Yumanity Therapeutics by 16.7% during the second quarter. Renaissance Technologies LLC now owns 70,508 shares of the company’s stock valued at $128,000 after acquiring an additional 10,100 shares during the period. Finally, Millennium Management LLC bought a new stake in Yumanity Therapeutics in the second quarter valued at about $155,000. 25.10% of the stock is currently owned by institutional investors.

About Yumanity Therapeutics

(Get Rating)

Yumanity Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration.

Featured Articles

Receive News & Ratings for Yumanity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yumanity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.